الصفحة الرئيسية>>Signaling Pathways>> Others>> Aldose reductase>>Ranirestat (AS-3201)

Ranirestat (AS-3201)

رقم الكتالوجGC31359

Ranirestat (AS-3201) (AS-3201) مثبط اختزال الألدوز (AR) الفعال والفعال عن طريق الفم مع IC50s من 11 نانومتر و 15 نانومتر لعدسة الفئران AR و AR المؤتلف البشري ، على التوالي ، و Ki 0.38 نانومتر لـ AR المؤتلف البشري .

Products are for research use only. Not for human use. We do not sell to patients.

Ranirestat (AS-3201) التركيب الكيميائي

Cas No.: 147254-64-6

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
263٫00
متوفر
5mg
239٫00
متوفر
10mg
414٫00
متوفر
50mg
1103٫00
متوفر
100mg
1839٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ranirestat (AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy.

[1]. Kurono M, et al. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability. Biochem Pharmacol. 2006 Jan 12;7 [2]. Matsumoto T, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009 Feb;109(2):203-10. [3]. Toyoda F, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. J Diabetes Res. 2014;2014:672590.

مراجعات

Review for Ranirestat (AS-3201)

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ranirestat (AS-3201)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.